{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:36Z","timestamp":1790173776652,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The US Food and Drug Administration recently approved sickle cell disease (SCD) gene therapies that require a contemporaneous cohort to compare their outcomes with those of individuals who did not receive gene therapy. Previously, we developed an automated algorithm to create a contemporaneous cohort of children and adults with SCD using electronic health record data. We tested the hypothesis that the updated Vanderbilt University Medical Center (VUMC) algorithm can identify individuals with SCD with sensitivity and specificity of &amp;gt;95%. In the VUMC health care system, we identified a cohort of 33\u2009141 adults and children of primarily African ancestry who underwent \u03b2-globin gene sequencing, with a 1.4% prevalence of SCD (473\/33\u2009141). For SCD, the performance of the VUMC algorithm using International Classification of Diseases (ICD) and laboratory data showed a sensitivity of 97.6% (462\/473), specificity of 99.9% (32\u2009663\/32 668), positive predictive value of 98.9% (462\/467), and negative predictive value of 99.9% (32\u2009663\/32\u2009674). Three SCD phenotypes account for 98.5% of the individuals in the cohort. The cohort had sensitivities of 96.8% (272\/281), 93.7% (136\/145), and 85% (34\/40) for hemoglobin SS (HbSS)\/Hb S\u03b20-thalassemia (HbS\u03b20), HbSC, and HbS\u03b2+, respectively. The cohort had a specificity of 99.9% across all 3 phenotypes: HbSS\/HbS\u03b20, HbSC, and HbS\u03b2+, respectively. We have developed an updated algorithm using ICD and laboratory data that accurately identifies individuals with SCD within a large health care system, and distinguishes HbSS\/HbS\u03b20, HbSC, and HbS\u03b2+.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018414","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:33:35Z","timestamp":1775075615000},"page":"4020-4027","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-2597","authenticated-orcid":false,"given":"Kristin","family":"Wuichet","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-9051","authenticated-orcid":false,"given":"Robert","family":"Corty","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bick","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael R.","family":"DeBaun","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"9","key":"2026060911315394200_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7109a1","article-title":"Surveillance for sickle cell disease - sickle cell data collection program, two states, 2004-2018","volume":"71","author":"Snyder","year":"2022","journal-title":"MMWR Surveill Summ"},{"key":"2026060911315394200_bib2","unstructured":"US Food & Drug Administration\n          . Long Term Follow-Up After Administration of Human Gene Therapy Products. Guidance for Industry. 2020. Accessed 3 August 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products."},{"issue":"3","key":"2026060911315394200_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.acap.2016.12.005","article-title":"Identification and validation of a sickle cell disease cohort within electronic health records","volume":"17","author":"Michalik","year":"2017","journal-title":"Acad Pediatr"},{"issue":"11","key":"2026060911315394200_bib4","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/bloodadvances.2018017541","article-title":"Identification of patients with hemoglobin SS\/S\u03b20 thalassemia disease and pain crises within electronic health records","volume":"2","author":"Singh","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2026060911315394200_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0033354919839072","article-title":"Improving an administrative case definition for longitudinal surveillance of sickle cell disease","volume":"134","author":"Snyder","year":"2019","journal-title":"Public Health Rep"},{"issue":"15","key":"2026060911315394200_bib6","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1182\/bloodadvances.2022008692","article-title":"Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026060911315394200_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-020-01457-x","article-title":"Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry","volume":"15","author":"Glassberg","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026060911315394200_bib8","doi-asserted-by":"crossref","first-page":"1277548","DOI":"10.3389\/frhem.2023.1277548","article-title":"Descriptive epidemiology of sickle cell disease in Tennessee: population-based estimates from 2008 to 2019","volume":"2","author":"Plaxco","year":"2023","journal-title":"Front Hematol"},{"issue":"7854","key":"2026060911315394200_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"issue":"D1","key":"2026060911315394200_bib9","doi-asserted-by":"crossref","first-page":"D1192","DOI":"10.1093\/nar\/gkaa959","article-title":"Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations","volume":"49","author":"Giardine","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2026060911315394200_bib10","doi-asserted-by":"crossref","first-page":"D925","DOI":"10.1093\/nar\/gkae977","article-title":"The evolution of dbSNP: 25 years of impact in genomic research","volume":"53","author":"Phan","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"45","key":"2026060911315394200_bib11","doi-asserted-by":"crossref","first-page":"e27522","DOI":"10.1097\/MD.0000000000027522","article-title":"Molecular genetics of \u03b2-thalassemia: a narrative review","volume":"100","author":"Jaing","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2026060911315394200_bib12","doi-asserted-by":"crossref","first-page":"e27352","DOI":"10.1002\/pbc.27352","article-title":"Children with HbS\u03b20 thalassemia have higher hemoglobin levels and lower incidence rate of acute chest syndrome compared to children with HbSS","volume":"65","author":"Day","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2026060911315394200_bib13","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.3390\/jcm9113782","article-title":"Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes","volume":"9","author":"Steinberg","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"2026060911315394200_bib14","doi-asserted-by":"crossref","first-page":"e28703","DOI":"10.1002\/pbc.28703","article-title":"Administrative data identify sickle cell disease: a critical review of approaches in U.S. health services research","volume":"67","author":"Grosse","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2026060911315394200_bib15","doi-asserted-by":"crossref","first-page":"e42816","DOI":"10.2196\/42816","article-title":"Evaluating the discriminatory ability of the sickle cell data collection program's administrative claims case definition in identifying adults with sickle cell disease: validation study","volume":"9","author":"Singh","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"23","key":"2026060911315394200_bib16","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2026060911315394200_bib17","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2026060911315394200_bib18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2026060911315394200_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"2026060911315394200_bib20","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2026060911315394200_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.15585\/mmwr.mm7312a1","article-title":"Birth prevalence of sickle cell disease and county-level social vulnerability - sickle cell data collection program, 11 states, 2016-2020","volume":"73","author":"Kayle","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4020\/2524648\/blooda_adv-2025-018414-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4020\/2524648\/blooda_adv-2025-018414-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:03Z","timestamp":1781019123000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/4020\/567534\/Accurate-identification-of-sickle-cell-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018414","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,6,2]]}}}